mylan is a global pharmaceutical company committed to setting new standards in healthcare. working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. we offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. in addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of hiv/aids patients in developing countries depend. we also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. learn more at mylan.com.
Company profile
Ticker
VTRS, 0A5V
Exchange
Website
CEO
Michael Goettler
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Upjohn Inc
SEC CIK
Corporate docs
Subsidiaries
Agila Australasia Pty Ltd • Alphapharm Pty. Ltd. • Mylan Australia Holding Pty Ltd • Mylan Australia Pty Limited • Upjohn Australia Pty Ltd • Viatris Pty. Ltd. • Arcana Arzneimittel GmbH • Mylan Österreich GmbH • Viatris LLC • Mylan BV ...
IRS number
834364296
VTRS stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
24 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Results of Operations and Financial Condition
7 Nov 23
ARS
2022 FY
Annual report to shareholders
3 Nov 23
DEFA14A
Additional proxy soliciting materials
3 Nov 23
DEF 14A
Definitive proxy
3 Nov 23
8-K
Regulation FD Disclosure
24 Oct 23
PRE 14A
Preliminary proxy
24 Oct 23
8-K
Departure of Directors or Certain Officers
20 Oct 23
8-K
Entry into a Material Definitive Agreement
2 Oct 23
Transcripts
VTRS
Earnings call transcript
2023 Q3
7 Nov 23
VTRS
Earnings call transcript
2023 Q2
7 Aug 23
VTRS
Earnings call transcript
2023 Q1
8 May 23
VTRS
Earnings call transcript
2022 Q4
27 Feb 23
VTRS
Earnings call transcript
2022 Q3
7 Nov 22
VTRS
Earnings call transcript
2022 Q2
8 Aug 22
VTRS
Earnings call transcript
2022 Q1
9 May 22
VTRS
Earnings call transcript
2021 Q4
28 Feb 22
VTRS
Earnings call transcript
2021 Q3
8 Nov 21
VTRS
Earnings call transcript
2021 Q2
9 Aug 21
Latest ownership filings
4
Xiangyang (Sean) Ni
24 Nov 23
144
Notice of proposed sale of securities
24 Nov 23
4
Leo Frans Groothuis
30 May 23
3
Leo Frans Groothuis
30 May 23
4
Scott Andrew Smith
4 Apr 23
4
JAMES M KILTS
6 Mar 23
4
MELINA E HIGGINS
6 Mar 23
4
ELISHA W FINNEY
6 Mar 23
4
RICHARD A MARK
6 Mar 23
4
W DON CORNWELL
6 Mar 23
Financial summary
| Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Institutional ownership, Q3 2023
77.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 908 |
| Opened positions | 86 |
| Closed positions | 103 |
| Increased positions | 298 |
| Reduced positions | 344 |
| 13F shares | Current |
|---|---|
| Total value | 9.12 tn |
| Total shares | 925.03 mm |
| Total puts | 3.75 mm |
| Total calls | 6.77 mm |
| Total put/call ratio | 0.6 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 142.60 mm | $1.41 tn |
| BLK Blackrock | 90.18 mm | $889.13 bn |
| Davis Selected Advisers | 64.06 mm | $631.67 bn |
| STT State Street | 61.09 mm | $602.34 bn |
| T. Rowe Price | 50.22 mm | $495.31 bn |
| IVZ Invesco | 28.24 mm | $278.44 bn |
| Geode Capital Management | 26.85 mm | $264.33 bn |
| Camber Capital Management | 20.00 mm | $197.28 bn |
| Deerfield Management | 19.86 mm | $195.85 bn |
| AMP Ameriprise Financial | 19.52 mm | $192.46 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 24 Nov 23 | Xiangyang (Sean) Ni | Common Stock | Sell | Dispose S | No | No | 9.3688 | 14,937 | 139.94 k | 64,658 |
| 23 Nov 23 | Xiangyang (Sean) Ni | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,363 | 0.00 | 79,595 |
| 23 Nov 23 | Xiangyang (Sean) Ni | Common Stock | Option exercise | Acquire M | No | No | 0 | 29,816 | 0.00 | 76,232 |
| 23 Nov 23 | Xiangyang (Sean) Ni | Dividend Equivalent Units Common Stock | Option exercise | Dispose M | No | No | 0 | 3,362.983 | 0.00 | 0 |
| 23 Nov 23 | Xiangyang (Sean) Ni | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 29,816 | 0.00 | 0 |
| 26 May 23 | Leo Frans Groothuis | RSU Common Stock | Grant | Acquire A | No | No | 0 | 21,954 | 0.00 | 21,954 |
| 1 Apr 23 | Smith Scott Andrew | RSU Common Stock | Grant | Acquire A | No | No | 0 | 407,485 | 0.00 | 407,485 |
| 4 Mar 23 | der Meer Mohr Pauline van | Common Stock | Payment of exercise | Dispose F | No | No | 11.13 | 22 | 244.86 | 40,245 |
| 4 Mar 23 | der Meer Mohr Pauline van | Common Stock | Option exercise | Acquire M | No | No | 0 | 705 | 0.00 | 40,267 |
| 4 Mar 23 | der Meer Mohr Pauline van | Common Stock | Payment of exercise | Dispose F | No | No | 11.13 | 589 | 6.56 k | 39,562 |
News
Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $11
22 Nov 23
5 Value Stocks To Watch In The Healthcare Sector
13 Nov 23
Viatris Revises Full-Year Total Revenues Guidance Range Solely To Reflect The Expected Negative Impact Of Foreign Exchange; Now Sees FY23 Revenue Down From $15.5B-$16B To $15.4B-$15.6B Vs $15.67B Est.
7 Nov 23
Recap: Viatris Q3 Earnings
7 Nov 23
Viatris Q3 2023 Adj EPS $0.79 Beats $0.74 Estimate, Sales $3.94B Miss $4.02B Estimate
7 Nov 23
Press releases
Viatris to Participate in the Jefferies London Healthcare Conference
14 Nov 23
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
13 Nov 23
Biosimilars Market Expected to Witness Massive Growth with a Tremendous CAGR of 21.54%, asserts DelveInsight | Companies – Pfizer Inc., Dr. Reddy's Laboratories Ltd., Amgen, Eli Lilly and Company
9 Nov 23
Viatris to Release Third Quarter 2023 Financial Results on November 7, 2023
10 Oct 23
Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA
1 Oct 23